IL239714A0 - Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases - Google Patents
Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseasesInfo
- Publication number
- IL239714A0 IL239714A0 IL239714A IL23971415A IL239714A0 IL 239714 A0 IL239714 A0 IL 239714A0 IL 239714 A IL239714 A IL 239714A IL 23971415 A IL23971415 A IL 23971415A IL 239714 A0 IL239714 A0 IL 239714A0
- Authority
- IL
- Israel
- Prior art keywords
- metformin
- diabetes
- disorders
- combinations
- treatment
- Prior art date
Links
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
- 229960003105 metformin Drugs 0.000 title 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 | |
| PCT/US2014/011394 WO2014113357A1 (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL239714A0 true IL239714A0 (en) | 2015-08-31 |
Family
ID=50030537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL239714A IL239714A0 (en) | 2013-01-17 | 2015-06-30 | Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150313908A1 (enExample) |
| EP (1) | EP2945618B1 (enExample) |
| JP (1) | JP6445459B2 (enExample) |
| KR (1) | KR102165434B1 (enExample) |
| CN (1) | CN104968341B (enExample) |
| AU (1) | AU2014207748B2 (enExample) |
| CA (1) | CA2896308C (enExample) |
| EA (1) | EA201591123A1 (enExample) |
| ES (1) | ES2687083T3 (enExample) |
| IL (1) | IL239714A0 (enExample) |
| MX (1) | MX366685B (enExample) |
| SG (2) | SG10201704716XA (enExample) |
| WO (1) | WO2014113357A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7239566B2 (ja) | 2017-09-22 | 2023-03-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| KR20260036616A (ko) * | 2018-05-08 | 2026-03-17 | 브이티브이 테라퓨틱스 엘엘씨 | Glp1r 작용제의 치료적 용도 |
| EP4141008A4 (en) | 2020-04-01 | 2024-04-17 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR |
| JP2023528565A (ja) | 2020-04-01 | 2023-07-05 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法 |
| JP7728872B2 (ja) * | 2020-12-31 | 2025-08-25 | ドン・クク・ファーム・カンパニー・リミテッド | 新規な溶出率を示すタダラフィルまたはこの薬学的に許容される塩及びデュタステリドまたはこの薬学的に許容される塩を含む医薬組成物 |
| KR20250075642A (ko) | 2022-09-21 | 2025-05-28 | 리제너론 파아마슈티컬스, 인크. | 비만, 당뇨병 및 간 기능 장애를 치료하는 방법 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| WO2007056387A2 (en) * | 2005-11-07 | 2007-05-18 | Elixir Pharmaceuticals, Inc. | Combinations of metformin and meglitinide |
| KR101616737B1 (ko) * | 2008-03-07 | 2016-05-02 | 브이티브이 테라퓨틱스 엘엘씨 | 당뇨병 치료를 위한 옥사디아조안트라센 화합물 |
| CA2757084C (en) * | 2009-03-30 | 2017-08-29 | Transtech Pharma, Inc. | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
| WO2011031620A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| DK2498802T3 (en) * | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
-
2014
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en not_active Ceased
- 2014-01-14 EA EA201591123A patent/EA201591123A1/ru unknown
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/ko active Active
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/es active Active
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/ja active Active
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/zh active Active
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 MX MX2015008555A patent/MX366685B/es active IP Right Grant
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2945618A1 (en) | 2015-11-25 |
| ES2687083T3 (es) | 2018-10-23 |
| SG11201504778UA (en) | 2015-07-30 |
| WO2014113357A1 (en) | 2014-07-24 |
| AU2014207748A1 (en) | 2015-07-09 |
| JP2016505039A (ja) | 2016-02-18 |
| HK1210424A1 (en) | 2016-04-22 |
| KR20150104572A (ko) | 2015-09-15 |
| MX366685B (es) | 2019-07-19 |
| CA2896308A1 (en) | 2014-07-24 |
| MX2015008555A (es) | 2016-01-22 |
| AU2014207748B2 (en) | 2018-10-11 |
| KR102165434B1 (ko) | 2020-10-14 |
| EA201591123A1 (ru) | 2015-11-30 |
| CN104968341A (zh) | 2015-10-07 |
| EP2945618B1 (en) | 2018-06-13 |
| SG10201704716XA (en) | 2017-07-28 |
| JP6445459B2 (ja) | 2018-12-26 |
| CN104968341B (zh) | 2020-06-09 |
| US20150313908A1 (en) | 2015-11-05 |
| CA2896308C (en) | 2021-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283979B (en) | 3,1-thiazol-2-yl converted benzamides | |
| IL245408A0 (en) | Converted benzamides for the treatment of arthropods | |
| IL240285A0 (en) | Biomarkers for type ii diabetes and their uses | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| PL3046470T3 (pl) | Diagnozowanie i leczenie zaburzeń ruchu | |
| IL239957A0 (en) | Assessment, testing and treatment of pkal mediated disorders | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| IL238027A0 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders | |
| IL243572B (en) | Drug combination for the treatment of melanoma | |
| SG10201704716XA (en) | Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders | |
| GB201314753D0 (en) | Wrist worn device | |
| GB2519982B (en) | Fungicidal composition and the use thereof | |
| PL3041441T3 (pl) | Orteza ręki do podtrzymywania kciuka szczególnie w przypadku rizartrozy | |
| IL242437B (en) | Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process | |
| PL3160464T3 (pl) | 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych | |
| IL241474A0 (en) | A device with joints for the wrist | |
| PL3074033T3 (pl) | Związki do leczenia otyłości i sposoby ich zastosowania | |
| GB201320506D0 (en) | Cyclic amino compounds for the use in the treatment of cardiac disorders | |
| EP3713604C0 (de) | Verbindung zur anwendung bei der steigerung von mentaler leistungsfähigkeit | |
| GB201800645D0 (en) | Monitoring medication consumption | |
| GB201314183D0 (en) | Status of type 2 diabetes | |
| GB201304197D0 (en) | Thumb pad embodiments | |
| TWM476976U (en) | Wrist pad | |
| TWM476582U (en) | Watch type stethoscope device |